First Report of NRG Oncology RTOG 0622: A Phase II Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk, Clinically Non-Metastatic Prostate Cancer after Radical Prostatectomy

Trial XXXX is a single-arm Phase II trial of men with high-risk prostate cancer after radical prostatectomy, enrolled at PSA failure but without clinical evidence of osseous metastases, who received Samarium-153 followed by salvage prostatic fossa radiation. Although this trial did not meet its primary endpoint of PSA response, it demonstrated the safety and tolerability of this regimen. The latter finding may support further use of Samarium-153 in high-risk, non-metastatic cases after radical prostatectomy.

http://ift.tt/2zTFIlO